Seattle Genetics (SGEN) 19.80 0.00

Seattle Genetics Inc /wa
(SGEN) 19.80 0.00

Last Trade:	19.79	Day Range:	19.76 - 20.145
Trade Time:	08:05PM	52wk Range:	12.29 - 22.40
Prev. Close:	19.79	Market Cap:	2.32B
Open:	19.88	Div Yield:	0
Volume:	1227478	PE:	-170
EPS:	-1.14

The Latest On SGEN

UPDATE: Seattle Genetics Announces Health Canada Accepts ADCETRIS® New Drug Submission for Review 5/23/12 9:02am

Seattle Genetics Announces Data from Investigator Trial of ADCETRIS in Relapsed Cutaneous T-Cell Lymphoma; Data Demonstrate 75 Percent Response Rate in Patients with Relapsed CTCL 5/10/12 10:01am

Seattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS™ in CD30-Positive Malignancies 4/12/12 9:19am

Notable Call Options Activity in Seattle Genetics 3/21/12 10:17am

Notable Put Options Activity in Seattle Genetics 2/13/12 12:35pm

Bank of America Optimistic Over Seattle Genetics' Adcetris 1/30/12 9:32am

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12 7:24pm

Seattle Genetics Announces Data from ADCETRIS in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma 1/26/12 5:04pm

Oppenheimer Reiterates Outperform, $26 PT On Seattle Genetics 1/13/12 3:12pm

A Peek Into The Market Before The Trading Starts 1/13/12 8:24am

Seattle Genetics Announces Updates to ADCETRIS Prescribing Information 1/13/12 7:45am

JPMorgan Confab Kicks Off Biotech 2012 1/5/12 12:46pm

UPDATE: Seattle Genetics Announces Health Canada Accepts ADCETRIS® New Drug Submission for Review 5/23/12

Seattle Genetics Announces Data from Investigator Trial of ADCETRIS in Relapsed Cutaneous T-Cell Lymphoma; Data Demonstrate 75 Percent Response Rate in Patients with Relapsed CTCL 5/10/12

Seattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS™ in CD30-Positive Malignancies 4/12/12

Notable Call Options Activity in Seattle Genetics 3/21/12

Notable Put Options Activity in Seattle Genetics 2/13/12

Bank of America Optimistic Over Seattle Genetics' Adcetris 1/30/12

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12

Seattle Genetics Announces Data from ADCETRIS in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma 1/26/12

Oppenheimer Reiterates Outperform, $26 PT On Seattle Genetics 1/13/12

A Peek Into The Market Before The Trading Starts 1/13/12

Seattle Genetics Announces Updates to ADCETRIS Prescribing Information 1/13/12

JPMorgan Confab Kicks Off Biotech 2012 1/5/12

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12

Oppenheimer Reiterates Outperform, $26 PT On Seattle Genetics 1/13/12

Best Biotech Stocks of 2011 12/27/11

Benzinga's M&A Chatter for Thursday December 15, 2011 12/15/11

Eight Stocks Insiders Are Buying 9/12/11

Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows 6/29/11

Mad Money Lightning Round OT: Cramer Is A Buyer Of SGEN, IBM, ANR 6/22/11

Stocks to Watch for 6/21/11: Fresh 52 Week Highs and Lows 6/21/11

Hoo-ah! Five Stocks to Consider on Al Pacino's Birthday 4/25/11

Mad Money Lightning Round: Cramer Likes CB Richard Ellis (SGEN, CBG, BIDU, SINA, ACW, CNH, POT) 3/25/11

Calls Purchased on Seattle Genetics, Inc. (SGEN) 1/27/11

NASDAQ Stocks Hitting 52-Week Highs (ACTL, SGEN, SIRI, DDMX) 10/4/10

Bank of America Optimistic Over Seattle Genetics' Adcetris 1/30/12

Oppenheimer Reiterates Outperform, $26 PT On Seattle Genetics 1/13/12

Jefferies Maintains Buy Rating and $28 PT on Seattle Genetics 12/2/11

UPDATE: JP Morgan Raises PT to $16 on Seattle Genetics 11/4/11

UPDATE: Piper Jaffray Downgrades Seattle Genetics to Neutral 11/4/11

JP Morgan Raises PT on Seattle Genetics to $16 11/4/11

Jefferies Maintains Buy Rating and $25 PT on Seattle Genetics 10/31/11

Bank of America Raises PO On Seattle Genetics to $22, Maintains Buy 10/18/11

UBS Changes PT on ADTN, VRUS, SGEN 10/13/11

Jefferies Maintains Buy Rating and $25 PT on Seattle Genetics 10/12/11

Goldman Sachs Resumes Seattle Genetics at Neutral 10/3/11

Goldman Sachs Resumes Seattle Genetics at Neutral, $20 PT 10/3/11

Trade SGEN
NOW!

Partner Headlines

Celldex Targeted Drug Shrinks Breast Cancer 5/23/12

7 Stocks Surging on Big Volume 5/18/12

ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 5/17/12

ASCO '12 Abstract Dump: Cancer Stocks in Focus 5/16/12

5 Stocks Set to Soar on Bullish Earnings 5/7/12

Celldex Screw-Up Nixes ASCO Data Slot 5/1/12

Seattle Genetics Inc. (SGEN) COO Eric Dobmeier sells 25,000 Shares 4/26/12

Seattle Genetics: A Cancer Niche Too Small 3/5/12

Seattle Genetics Inc. (SGEN) COO Eric Dobmeier sells 4,000 Shares 3/1/12

Press Releases

Seattle Genetics Announces Health Canada Accepts ADCETRIS® New Drug Submission for Review 5/23/12 Business Wire

Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting 5/16/12 Business Wire

Seattle Genetics to Present at Bank of America Merrill Lynch Health Care Conference 5/11/12 Business Wire

Seattle Genetics Announces Data from Investigator Trial of ADCETRIS™ in Relapsed Cutaneous T-Cell Lymphoma 5/10/12 Business Wire

Seattle Genetics Reports First Quarter 2012 Financial Results 5/8/12 Business Wire

Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma 5/7/12 Business Wire

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2012 Financial Results on May 8, 2012 4/24/12 Business Wire

Seattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS™ in CD30-Positive Malignancies 4/12/12 Business Wire

Seattle Genetics Demonstrates Continued Leadership in Antibody-Drug Conjugates at AACR 4/3/12 Business Wire

Seattle Genetics to Present at Needham Healthcare Conference 3/29/12 Business Wire

Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of Clinical Oncology 3/26/12 Business Wire

Seattle Genetics Appoints Dr. Nancy Simonian to Board of Directors 3/21/12 Business Wire

Get the latest SGEN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Seattle Genetics Inc /wa stock price.

Seattle Genetics Inc /wa by YCharts

Seattle Genetics (SGEN) 19.80 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On SGEN

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social